Welcome to “MS News Notes,” a column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Could MS be predicted by an artificial intelligence tool? Wouldn't it be great if there was a way to predict whether or not someone was likely to develop MS? As MS News Today reports in "AI model is able to predict MS risk years before disease onset," that may be possible someday. According to the story, researchers have used an algorithm that "suggests that AI-based prediction models could identify the risk for multiple sclerosis years before neurological symptoms appear." The researchers built this type of model using data including age, gender, metabolic information, and blood markers from 3,000 people, some with MS and some without. The results reportedly were very accurate at predicting MS risk. A tool like this would certainly be useful in identifying people who should be watched carefully if they develop symptoms suggesting an MS diagnosis. But that raises the question, at least with me, of how early to begin treating those people with a disease-modifying therapy (DMT). Would it be any earlier in the diagnostic process than it is now? Another report that bacteria in your gut might trigger MS. Researchers have been studying a possible connection between gut bacteria and MS for a number of years. The story "Gut bacteria may be key to activate immune cells that trigger MS" looks at another study that suggests this. Specifically, these researchers report that immune cells that target myelin appear to be triggered in the gut before moving into the brain and launching an inflammatory attack there. I'm approaching the 43rd anniversary of my MS diagnosis in a couple weeks, so it's probably too late for me to do much to correct what's happening in my gut. But whether it has an impact on my MS or not, I recently started to eat a healthier diet. As they say, it can't hurt. WHO lists 3 'essential' DMTs. "Three MS therapies listed as WHO essential medicines" brings word of a decision that's important to people with MS in many parts of the world. "Glatiramer acetate (sold as Copaxone with generics available), Mavenclad (cladribine), and rituximab made the [World Health Organization's] list because of their ability to safely and cost-effectively slow or delay the disease’s progression," the story notes. As MS News Today reported in March, the MS International Federation applied for the inclusion of these DMTs on the WHO list to assure that helpful treatments are available to people in lower- and middle-income countries. Their effort is commendable. I hope the health services in those countries move quickly to provide access to these important MS therapies. The WHO list "is updated every two years and compiles medications that are of high priority, safe, and cost-effective, and should be available as part of any functioning healthcare system," the story adds. Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Multiple Sclerosis News Today or its parent company, BioNews, and are intended to spark discussion about issues pertaining to multiple sclerosis.